|
Overview
|
|
Headed by a strong pool of 400+ scientists and researchers, R & D is the key growth driver for Intas. Its constant quest for developing new products and technology has led breakthrough innovations in a wide spectrum of areas such as Oncology, hormones & NDDS, apart from other generic products. Till date, Intas has filed 50+ patents on novel formulations, API polymorphs/processes & analytical methods to its credit. Intas's continuous R & D initiatives have strengthened its product basket with delivery of niche and complex products. Intas is extensively working on Para IV and 505 (b) 2 products for USA market and few products are already filed with USFDA. Intas targets to file more than 5 Para IV applications to US market each year. Intas Pharmaceuticals is engaged in research, development and commercialization of novel therapeutic products for the treatment of cancer, infectious diseases and acute medical emergencies. The company in collaboration with US based Jina Pharmaceuticals Inc. has developed a clinically validated proprietary Nanoaqualip™ technology to formulate drug products. The newly formulated drugs are less toxic with improved bioavailability and better therapeutics. Based on Nanoaqualip™ technology the company is enhancing broader applications of generic drugs, difficult to formulate drugs and drugs of which the patent rights are near expiration through the development of improved delivery system. The company is also focused on discovery and development of New Chemical Entity (NCE’s) targeting cancer and neurodegenerative diseases such as bipolar disorder. The molecule has completed Phase-Ib Clinical Studies & entering into Phase-II Efficacy Studies. Intas's R & D strategies are focused on 2 major areas: 1. Pharmaceutical Formulation Development Intas's primary focus area in formulation development includes:
2. API Development Intas's primary focus area of API development R & D team is:
|